Innovation1 Biotech Inc. (IVBT) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
179 RTE 46W, SUITE 15 #147 ROCKAWAY, NJ 07866 |
| State of Incorp. | NV |
| Fiscal Year End | August 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 11/30/2023 MRQ | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | 8/31/2019 | 8/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 156 | 137 | 18 | 19 | 774 | ||||
| Cash and cash equivalent | 156 | 137 | 18 | 19 | 774 | ||||
| Receivables | 56 | 0 | |||||||
| Inventory, net of allowances, customer advances and progress billings | 17 | 37 | 204 | 53 | |||||
| Inventory | 17 | 37 | 204 | 53 | |||||
| Prepaid expense | 15 | 74 | 14 | 14 | 26 | 30 | |||
| Other undisclosed current assets | 58 | 133 | |||||||
| Total current assets: | 73 | 287 | 168 | 202 | 248 | 858 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 482 | ✕ | |||||||
| Property, plant and equipment | 2 | 3 | 1 | 2 | 7 | 2 | |||
| Long-term investments and receivables | 11 | 3 | |||||||
| Long-term investments | 11 | 3 | |||||||
| Intangible assets, net (including goodwill) | 2 | 42,982 | 2 | 2 | 2 | 3 | |||
| Intangible assets, net (excluding goodwill) | 2 | 42,982 | 2 | 2 | 2 | 3 | |||
| Other undisclosed noncurrent assets | 210 | ||||||||
| Total noncurrent assets: | 3 | 43,676 | 13 | 6 | 8 | 5 | |||
| TOTAL ASSETS: | 76 | 43,963 | 182 | 209 | 256 | 863 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1,421 | 1,103 | 44 | 443 | 84 | 100 | |||
| Interest and dividends payable | ✕ | ✕ | 838 | 138 | 74 | 24 | 4 | ||
| Accounts payable | 349 | 109 | 95 | ||||||
| Accrued liabilities | 1,072 | 157 | 1 | 0 | |||||
| Other undisclosed accounts payable and accrued liabilities | (94) | 370 | 60 | ||||||
| Debt | 10 | 10 | 160 | 10 | 50 | 50 | |||
| Due to related parties | ✕ | ✕ | 65 | 73 | |||||
| Other undisclosed current liabilities | 1,856 | 28,699 | 138 | 2,360 | 90 | 537 | |||
| Total current liabilities: | 3,287 | 29,812 | 407 | 2,887 | 224 | 687 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 298 | ||||||||
| Liabilities, other than long-term debt | 498 | ||||||||
| Lease deposit liability | 498 | ✕ | |||||||
| Operating lease, liability | 298 | ✕ | |||||||
| Other undisclosed noncurrent liabilities | 219 | 10,502 | |||||||
| Total noncurrent liabilities: | 219 | 11,298 | |||||||
| Total liabilities: | 3,506 | 41,111 | 407 | 2,887 | 224 | 687 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (3,430) | 2,853 | (225) | (2,678) | 32 | 176 | |||
| Preferred stock | 8 | 8 | 8 | ||||||
| Common stock | 20 | 20 | 0 | 58 | 135 | 133 | |||
| Common stock, value, subscriptions | 160 | ||||||||
| Additional paid in capital | 55,172 | 47,376 | 2,746 | 1,100 | 942 | 868 | |||
| Accumulated deficit | (58,630) | (44,551) | (2,974) | (3,844) | (1,214) | (993) | |||
| Other undisclosed equity, attributable to parent | 8 | 8 | 3 | 160 | |||||
| Total equity: | (3,430) | 2,853 | (225) | (2,678) | 32 | 176 | |||
| TOTAL LIABILITIES AND EQUITY: | 76 | 43,963 | 182 | 209 | 256 | 863 | |||
Income Statement (P&L) ($ in thousands)
| 11/30/2023 TTM | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | 8/31/2019 | 8/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 3 | 1 | 79 | 17 | ||||
| Cost of revenue | (1) | (3) | (129) | (81) | ||||
| Gross profit: | 2 | (2) | (50) | (64) | ||||
| Operating expenses | (1,367) | (41,030) | (241) | (215) | (618) | (372) | ||
| Other undisclosed operating income | ||||||||
| Operating loss: | (1,367) | (41,030) | (239) | (217) | (668) | (436) | ||
| Nonoperating income (expense) | 4,621 | (152) | (2,733) | 2,932 | (498) | (539) | ||
| Investment income, nonoperating | (1,454) | 568 | ||||||
| Other nonoperating income (expense) | 4,621 | (152) | (1,279) | 2,363 | (498) | (539) | ||
| Interest and debt expense | (171) | (144) | (115) | (870) | (1) | (2) | ||
| Income (loss) from continuing operations: | 3,083 | (41,326) | (3,087) | 1,845 | (1,166) | (977) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | (41,326) | (3,087) | 1,845 | (1,166) | (977) | |
| Other undisclosed net income (loss) | 448 | 3,111 | 996 | |||||
| Net income (loss): | 3,083 | (40,878) | 24 | 1,845 | (170) | (977) | ||
| Other undisclosed net income (loss) attributable to parent | (9,071) | 1,016 | (4,425) | 2 | ||||
| Net income (loss) attributable to parent: | (5,988) | (40,878) | 1,040 | (2,580) | (170) | (976) | ||
| Other undisclosed net loss available to common stockholders, basic | (8,091) | (700) | ||||||
| Net income (loss) available to common stockholders, diluted: | (14,079) | (41,577) | 1,040 | (2,580) | (170) | (976) | ||
Comprehensive Income ($ in thousands)
| 11/30/2023 TTM | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | 8/31/2019 | 8/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 3,083 | (40,878) | 24 | 1,845 | (170) | (977) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 3,083 | (40,878) | 24 | 1,845 | (170) | (977) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.